RL

Rekha Lalabahadur

Active Director Director DIN 02495918
DIN 02495918 First appointment Mar 2009 Primary industry Trading
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Mar 2009
Shareholding value •••• Premium profile

About Rekha Lalabahadur

Data last updated:

Rekha Lalabahadur is a Director at Uad Pharma Private Limited (since 2009). The company operates in Trading. Uad Pharma Private Limited reported revenue of ₹60,998 (FY 2024).

DIN 02495918
Primary Designation Director
Industry Trading
First Appointment 06 Mar 2009
Oldest Company Age 17 yrs
Largest company Uad Pharma Private Limited · ₹60,998 (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Uad Pharma Private Limited U74900DL2009PTC188279
Director06 Mar 20092009₹60,998 (FY 2024)Active

Board colleagues of Rekha Lalabahadur

NameDINCompanyDesignation
Devendra Singh02480189Uad Pharma Private LimitedDirector

Directorship timeline

Open interactive timeline →
Uad Pharma Private Limited
Premium access

Shareholding and investment profile for Rekha Lalabahadur

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Rekha Lalabahadur

Rekha Lalabahadur currently holds 1 directorship: Uad Pharma Private Limited (Director, since 06 Mar 2009, revenue ₹60,998 (FY 2024)).

Rekha Lalabahadur was first appointed on 06 Mar 2009 as Director at Uad Pharma Private Limited.

The current boards of Rekha Lalabahadur's companies include Devendra Singh (Uad Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available